There are no grade 3 or 4 adverse events or aggravations of renal insufficiency during the third-line therapy.<h4>Discussion</h4>RC48 combined with pembrolizumab demonstrated outstanding efficacy and safety in this HER2-positive metastatic UC patient. The gene discussed is ERBB2; the disease is Renal insufficiency.